Association For Innovation And Biomedical Research On Light And Image
- Address
- lock Available on a paid plan
Eye Diseases and Ocular Physiology
The Association For Innovation And Biomedical Research On Light And Image in Coimbra is conducting clinical trials focused on eye diseases and ocular physiological phenomena. The research is centered on improving vision outcomes and slowing disease progression in conditions that affect the retina and other parts of the eye.
- Studies in diabetic macular edema and uveitic macular edema aimed at testing new treatment options and comparing them with established care
- Research in age-related macular degeneration, including atrophic AMD, geographic atrophy, and macular neovascularization, to evaluate therapies that may preserve vision
- Trials examining visual acuity and other functional eye outcomes to measure how well new approaches improve day-to-day sight
This portfolio reflects a strong emphasis on retinal disease research, with studies designed to assess whether emerging therapies can match or improve current treatments while supporting better long-term eye health.
Immune System Diseases and Eye-Related Inflammation
The site also supports research in immune system diseases that affect the eyes, especially moderate-to-severe thyroid eye disease. These trials explore whether new therapies can reduce inflammation and improve visible eye changes linked to autoimmune activity.
- Clinical research in thyroid eye disease focused on easing symptoms and improving eye appearance and function
- Studies assessing treatment effectiveness in inflammatory macular conditions where the immune system contributes to vision loss
- Work aimed at identifying safer and more effective ways to manage immune-mediated ocular disease
At this Clinical Trial Centre, the immune-focused studies complement the retinal programs by addressing eye conditions where inflammation plays a major role in disease burden and quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Eyebiotech Limited1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eyebiotech Limited3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Association For Innovation And Biomedical Research On Light And Image
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorescein Sodium | 4 | Unknown | 2023-09-13 | 2026-06-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.